The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic ...

Avalere Health , a global strategic healthcare partner, announces a new commitment to make EVERY PATIENT POSSIBLE. The ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Flagship’s Pioneering Medicines initiative could acquire Omega’s assets via a stalking horse bid, according to a regulatory ...